PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage

Aim: To study the influence of the therapy PPAR-alpha agonist (fenofibrate) in exacerbation dynamics of severe stage of chronic obstructive pulmonary disease (AECOPD) patients. Methods: Peripheral blood samples were collected from 20 patients with severe AECOPD receiving conventional therapy with 145 mg fenofibrate (1 tablet once a day No. 10) and 21 patients with severe AECOPD and 20 man from control group. Lymphocytes were isolated by two-color labeled monoclonal antibodies flow cytometry to examine the quantities and percentage of, CD3+CD19- T cell, CD3-CD19+ B cell, CD3+CD4+ T cell, CD3+CD8+ T cell, respectively. Enzyme immunodetection was used to detect the expression of tumor necrosis factor α (TNF-α). All patients underwent a spirography with broncholytic breakdown. Mann-Whitney test was used for comparison between data before and after treatment an control group. Results: Complex therapy with inclusion of fenofibrate significantly increased the indicators of TNF-a, compared with conventional therapy (p<0.05). This increase was accompanied by a significant increase in levels of FVC, FEV1/FVC, MEF75, MEF 25 and VC MAX, compared with the group receiving conventional therapy (p<0.05). Conclusion: Fenofibrate in addition to the direct immunomodulating effect, significantly improves the function of external respiration. Statistically significant increase in the level of TNF-alpha may be associated with activation of apoptosis phagocytic cells, leading to the limitation of the systemic inflammatory response in the body.